What Pharma Can Learn From Military Intelligence
August 21, 2026
Former military intelligence officer Tony Page discusses what pharma can learn from early warning systems, decision cycles, and the discipline of intelligence
5 min read
False
Advertisement
2026
Musings from The Power List: Daniel Vitt
August 20, 2026
From multiple sclerosis to AI-driven discovery, Daniel Vitt reflects on the future of drug development
6 min read
The Road to Commercial-Scale iPSC Cell Therapy
August 19, 2026
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
5 min read
The Mindset for Success in Biopharma's New Multipolar World
August 18, 2026
From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market
10 min read
Biopharma Labs Have an Integration Debt Problem
August 17, 2026
Biopharma labs are investing heavily in digital tools, but without trusted data architecture, each new platform can add another point of failure
5 min read
This Week’s CGT News: T-Cell Therapy Clears Pediatric Solid Tumor
August 17, 2026
PRAME-targeted T cells produce a complete response in metastatic nephroblastoma, CAR T cells remain active after a decade, and an in vivo CRISPR screen identifies edits that strengthen solid-tumor activity
3 min read
Musings from The Power List: John Maher
August 14, 2026
John Maher discusses the scientific and practical challenges of bringing CAR T-cell therapies to patients with solid tumors
4 min read
Why Cell Therapy Needs a Digital Backbone
August 13, 2026
Alexander Seyf on why the UK is losing ground in cell and gene therapy, the real bottlenecks to commercialization, and why digitalization is no longer optional
8 min read
Can Exosomes Unlock Nanomedicine’s Regenerative Medicine Potential?
August 12, 2026
NurExone CEO Lior Shaltiel discusses the company’s exosome-based approach to nerve regeneration, the manufacturing hurdles facing the field, and what it will take to bring nanotechnology therapeutics to patients
11 min read
Musings from The Power List: Ann Cleves
August 11, 2026
Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five
3 min read
